Download image

VM Pramipexole

Visual representation of the interaction
Mode of action
Pramipexole
Transporter zone
No interaction
Enzyme zone
No interaction
Receptor zone
Contributes to other effects
Important for clinical effects
Ion channel zone
No interaction
Date published
10.02.2017

Pramipexole

For more detailed explanation of the principles of the VM Library
For more detailed explanation of the Neuroscience based Nomenclature

Please notice that Caution should be applied when extrapolating animal data to humans.

Detailed and Approved Information on the clinical use of the compounds can be found at the homepage of EMA or at Martindale.

References
  1. Fox SH, Katzenschlager R, Lim SY, et al. (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord 26 Suppl 3: S2-41.
  2. Kulisevsky J and Pagonabarraga J. (2010) Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials. Drug Saf 33: 147-161.
  3. Millan MJ, Maiofiss L, Cussac D, et al. (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303: 791-804.
  4. Newman-Tancredi A, Cussac D, Audinot V, et al. (2002a) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther 303: 805-814.
  5. Newman-Tancredi A, Cussac D, Quentric Y, et al. (2002b) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 303: 815-822.
  6. Seeman P. (2015) Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 69: 183-189.
Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country